近日，中央经济工作会议在北京举行，会议总结了2025年经济工作，并对2026年经济发展作出重要部 署，强调要"坚持创新驱动，加紧培育壮大新动能"，"坚持'双碳'引领，推动全面绿色转型"等。在这一 政策导向与宏观背景下，企业如何以实际行动响应国家战略、实现高质量可持续发展，成为各界关注的 焦点。 我们注意到，众多企业将ESG理念作为践行长期主义的核心原则，在实现自身稳健发展的同时，为国家 和社会的可持续发展贡献力量。如新集团便是其中的坚定践行者。2025年，其坚守"善的力量"企业使 命，积极贯彻新发展理念，在科技创新、绿色转型、民生责任等方面扎实作为，斩获多项权威荣誉。这 些奖项既是行业与市场对如新四十余年深耕美丽健康产业的高度认可，更是对其"科技引领、品质至 上、责任先行"发展理念及扎实ESG实践的有力印证，也与中央经济工作会议所倡导的高质量发展方向 高度契合。 欧睿国际最新调研数据显示，如新是 2023 和 2024 连续两年全球零售额第一的美容与健康仪器系列公司 （数据源自 Euromonitor International Limited；按 2023 和 2024 全球各公司居家美容与健康仪器系列整 ...

新征程呼唤新作为，新篇章更需勇担当。2026年，我将带领天赐材料全体同仁，坚守实业初心、深耕主 业根基，持续加大科技创新力度，引领绿色化学实践，稳步拓展全球产业版图，深度拥抱资本市场。愿 与各界朋友携手并肩、同心致远，在"十五五"的壮阔征程中，以材料创新赋能全球产业升级，共绘高质 量发展的奋进新蓝图！ 作为天赐材料董事长，我始终坚信，未来五年将是锂电与储能产业的全新增长周期，而高水平科技创新 正是企业把握行业机遇、乘势而上的核心动力。我们将持续保持高水平研发投入，依托自有研发创新平 台，深化"领域—产品—技术"一体化创新研发模式，加速前沿科技成果产业化落地，让每一项创新都成 为壮大新质生产力的坚实支撑，全面强化公司在全球产业链、供应链、价值链中的核心竞争优势。 立足全球视野，我们将持续深化全球化战略布局。依托核心技术与卓越品质优势，进一步扩大北美、欧 洲、东南亚等重点区域市场份额，加速布局海外研发生产基地，实现产能落地与本土化服务的协同共 进。我们秉持开放共赢理念，持续深化与核心客户的战略合作，丰富客户结构，同时借助资本市场的资 源配置功能，整合全球优质创新资源与产业资源，锤炼新质生产力的国际竞争力，全力擦亮 ...

作为天赐材料董事长，我始终坚信，未来5年将是锂电与储能产业的全新增长周期。2026年，我将带领 天赐材料全体同仁，坚守实业初心、深耕主业根基，持续加大科技创新力度，引领绿色化学实践，稳步 拓展全球产业版图，深度拥抱资本市场。愿与各界朋友携手并肩、同心致远，在"十五五"的壮阔征程 中，以材料创新赋能全球产业升级，共绘高质量发展的奋进新蓝图！ （文章来源：证券时报） 岁序更迭，骏业日新。作为深耕精细化工材料领域的上市公司，站在"十五五"开局的关键节点，我深知 肩负的时代使命与社会责任。 2025年，在全体同仁的凝心聚力下，我们取得里程碑式成果。"十五五"启幕之际，我们将持续锚定"一 体化"+"全球化"，秉持"绿色化学、循环经济、智能制造"的可持续发展核心理念，深耕锂离子电池材 料、日化材料及特种化学品两大核心主业，持续增强公司创新发展动能与全球综合竞争力。 ...

中化新网讯 近日，德国生物技术与绿色化学公司Bioweg UG宣布，已获得德国政府150万欧元的资金支 持，用于开发从废水中回收稀土元素(REEs)的技术。该项目正与柏林工业大学合作进行。 Bioweg联合创始人兼首席执行官普拉提克·马哈尔瓦尔表示："这笔资助将使我们能够加速与柏林工业大 学合作，开发一个可持续、基于生物技术的稀土回收平台。该平台建立在Bioweg基于废物流的发酵平 台和绿色化学技术专长之上，可扩展我们已大规模应用于细菌纤维素生产的能力。" 此项资金来源于德国创新署发起的"技术金属转型挑战"计划。据Bioweg介绍，该计划旨在"开发和验证 从复杂废物流中回收关键金属的创新工艺，包括采用选择性水基方法，以获得适用于下游应用的高纯度 产出。" ...

Group 1 - The company Changlian Technology (301618) has achieved the highest level of ZDHC MRSL compliance, receiving the 2025 adiFORMULATOR AWARD CHAMPION from international sports brand ADIDAS, marking a significant recognition of China's capabilities in high-end eco-friendly chemicals [1] - Achieving ZDHC MRSL compliance level 3 requires source innovation starting from molecular structure design, including water-based technology systems and non-toxic formulations, ensuring products meet or exceed stringent international standards [1] - The company has eliminated VOC emissions from traditional solvent-based products, using water as a medium to ensure green safety throughout production and usage, while maintaining excellent weather resistance and printing effects [1] Group 2 - As a nationally certified manufacturing champion, Changlian Technology has been deeply involved in the water-based printing materials sector for decades, breaking foreign technology monopolies with its core product—eco-friendly water-based printing paste [2] - The products are recognized for their stability, printing adaptability, and environmental friendliness, widely used in textiles, sportswear, electronics, crafts, and eco-friendly packaging, receiving high acclaim from well-known domestic brands [2] - The company plans to continue focusing on its core business, increasing R&D investment in eco-friendly new materials, and embedding green chemistry concepts into product innovation for sustainable industry development [2]

Core Viewpoint - The pre-dispersed rubber additive masterbatch industry is rapidly developing, driven by the demand for environmentally friendly and efficient production processes, with significant growth potential in various applications, particularly in the automotive sector [4][5][10]. Group 1: Product Definition and Market Overview - Pre-dispersed rubber additive masterbatch refers to granulated products where rubber processing additives are pre-dispersed in a rubber matrix, enhancing processing performance and product quality [3]. - The industry has seen a low market concentration, with over 80,000 tons of production from more than a dozen member units of the China Rubber Industry Association, while the number of production enterprises exceeds several dozen [4]. Group 2: Market Growth and Trends - The market for rubber additives is experiencing rapid growth, aligning with the trends of green chemistry and the increasing demand for high-performance rubber products [5][9]. - The global market for rubber additive masterbatch is projected to reach 14.164 billion yuan in 2024, with an expected CAGR of 4.77% from 2025 to 2031 [17]. Group 3: Industry Challenges - The penetration of pre-dispersed rubber additive masterbatch in the tire sector is limited due to the complexity of tire formulations, which involve over 200 variables, making it difficult for companies to adopt these additives [6]. - The confidentiality of tire formulations serves as a competitive barrier, hindering the widespread use of pre-dispersed masterbatch in the industry [6]. Group 4: Technological Innovations - The application of nanotechnology in rubber additives, such as nano zinc oxide and nano silica, is expected to enhance the mechanical properties and durability of rubber products [10]. - The integration of AI, IoT, and big data in production processes is anticipated to improve automation, quality control, and overall production efficiency [10]. Group 5: Policy and Regulatory Environment - China's policies are focused on encouraging technological innovation, promoting green development, and enhancing industry regulation, particularly for high-performance and environmentally friendly rubber additives [22][23]. - The government is actively pushing for the elimination of low-end, high-pollution additives, steering the industry towards more efficient and sustainable practices [22].

Summary of the Earnings Call for Yaoshi Technology Q3 2022 Company Overview - **Company**: Yaoshi Technology - **Industry**: Pharmaceutical and Biotechnology - **Earnings Report**: Q3 2022 Key Financial Highlights - **Total Revenue**: 419 million, a year-on-year increase of 25.81% [2] - **Revenue from Drug Development and Commercialization**: 1.179 billion, a year-on-year increase of 34.9% [2] - **Net Cash Flow from Operating Activities**: 543 million, a year-on-year increase of 187.74% [3] - **Total Expenses**: 283 million, a year-on-year decrease of 9.88% [20] - **Gross Margin**: Stable around 30% [43] Strategic Focus and Growth Drivers - **Customer Base**: Revenue from large multinational pharmaceutical companies (MNCs) increased by 68.1%, now accounting for 36% of total revenue [8] - **New Orders**: CDMO new orders increased by over 15%, with orders for new businesses like peptides and ADCs growing over 100% [3] - **Investment in Technology**: The company is focusing on enhancing its technical services and CMC (Chemistry, Manufacturing, and Controls) capabilities to deepen ties with core customers [3][45] - **Production Capacity**: The new 503 workshop started in February 2025, with a current capacity utilization rate of 60%-70% expected to reach 70% by 2026 [12][13] Market Trends and Future Outlook - **Demand Improvement**: Domestic and international demand is improving, driven by policy changes and increased investment in innovative drugs [18] - **Project Pipeline**: Over 1,100 early clinical projects completed, with 53 projects in Phase III and commercialization, showing significant growth compared to the previous year [16] - **New Molecule Business**: Focus on XDC, TBD, peptides, and oligonucleotides, with a projected increase in orders exceeding 100% [50] - **Long-term Strategy**: The company has a three-year strategic plan aimed at consistent annual growth, with confidence in achieving industry-standard performance [59] Risks and Challenges - **Short-term Margin Pressure**: The company is currently in a strategic investment phase, which may pressure short-term margins but is expected to stabilize and improve in the long run [3][45] - **Capacity and Order Matching**: While current capacity is adequate for existing orders, the company is actively working to expand capacity to meet future demand [12][13] Additional Insights - **Brand Promotion**: The company is enhancing its brand presence through participation in industry forums and direct engagement with clients [11] - **Collaboration with MNCs**: The company is expanding its collaboration with MNCs, moving from early-stage projects to more comprehensive partnerships [10][39] - **Focus on Green Chemistry**: The company is committed to green chemistry initiatives, which are becoming increasingly important for collaboration with MNCs [41] This summary encapsulates the key points from the earnings call, highlighting the financial performance, strategic initiatives, market trends, and future outlook for Yaoshi Technology in the pharmaceutical industry.

Group 1: Financial Performance - The company achieved a revenue of 1.419 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 25.81% [2] - Revenue from drug development and commercialization reached 1.179 billion yuan, with a year-on-year increase of 34.91% [2] - The net cash flow from operating activities significantly improved to 543 million yuan, up 187.74% year-on-year, indicating enhanced operational efficiency [2] Group 2: Client and Market Development - Revenue from multinational pharmaceutical companies (MNCs) reached 514 million yuan, growing by 68% year-on-year, accounting for 36% of total revenue [3] - New orders in the CDMO sector increased by 15%, with orders for peptides and ADCs growing over 100% [2] - The company is focusing on deepening collaborations with leading global pharmaceutical companies, enhancing client retention [2] Group 3: Capacity and Technology Investments - The 503 workshop was launched in February 2025, adding a capacity of 190 m³, with expectations to reach full utilization by 2026 [3] - The company plans to expand its TIDES research team to approximately 100 members by the end of 2025 and is constructing a new R&D building [5] - Capital expenditures will focus on expanding new molecular capacities, integrating low-carbon chemical technologies, and strategic overseas site development [5] Group 4: Cost Management and Future Outlook - Total sales, management, R&D, and financial expenses for the first three quarters of 2025 were 283 million yuan, a decrease of 9.88% year-on-year [4] - The company anticipates a rise in R&D expenses due to ongoing investments in AI pharmaceuticals and continuous flow chemistry [4] - The outlook for global CDMO demand remains optimistic, driven by favorable market conditions and increased investment in next-generation therapies [4] Group 5: Geographic Revenue Distribution - Approximately 70% of total revenue comes from overseas markets, with North America contributing about 50% and Europe around 15% [8] - Domestic market revenue accounts for about 30%, with a notable increase in demand from domestic biotech companies [8] - The company expects strong growth potential from the domestic biotech sector due to improved financing conditions and accelerated new drug approvals [8]

Core Viewpoint - The ionic liquid market is experiencing steady growth driven by increasing demand for environmentally friendly alternatives, with a projected market size of $156 million by 2025 and a compound annual growth rate (CAGR) of approximately 9.39% over the next five years [2][7]. Group 1: Product Definition and Scope - Ionic liquids are liquid salts formed by organic cations and inorganic or organic anions, characterized by their ionic composition and low melting points [1]. Group 2: Current Industry Status - The ionic liquid market is expanding due to the global demand for eco-friendly alternatives, with the Asia-Pacific region being the fastest-growing market due to strong manufacturing bases and increased research investment [2]. - By 2024, the global ionic liquid market is expected to reach $142 million, with a forecasted growth to $267 million by 2031 [7]. Group 3: Technological Advances and Innovations - Advances in synthesis methods are leading to greener and more scalable production of ionic liquids, reducing costs and improving purity [3]. - The development of functionalized ionic liquids is enhancing their catalytic properties and adaptability for specific applications, such as magnetic and bio-based ionic liquids [3]. Group 4: Expansion of Application Areas - Ionic liquids are increasingly being used in high-growth sectors such as environmental protection, electrochemical energy storage, materials preparation, and biomedicine [4]. - In environmental applications, ionic liquids are utilized for CO2 capture, wastewater treatment, and heavy metal recovery, aligning with global carbon neutrality goals [4]. Group 5: Future Development Trends - The diversification of ionic liquid products is driven by technological innovations, with new types such as magnetic and responsive ionic liquids emerging for various applications [5]. - The rapid development of the electrochemical and energy sectors is making ionic liquids key materials for energy storage and conversion devices, enhancing energy density and cycle life [5]. - The push for green chemistry is leading to the replacement of traditional organic solvents with low-volatility, low-toxicity ionic liquids, which significantly reduce harmful emissions [5]. Group 6: Global Market Analysis - Major producers of ionic liquids include BASF, Evonik Industries, Solvay, Merck, and KOEI Chemical, with the top five companies holding nearly 65% of the market share [7][11]. - The primary consumption regions for ionic liquids are Europe, North America, China, and Japan, with Southeast Asian countries showing significant market potential due to rapid economic growth [7]. Group 7: Policy and Regulatory Environment - The Chinese government is promoting the ionic liquid industry through various policies aimed at green manufacturing and sustainable development, encouraging the adoption of ionic liquids in multiple sectors [8]. - Policies supporting green chemistry and carbon neutrality are expected to drive market demand for ionic liquids, facilitating their transition from laboratory-scale to industrial-scale applications [8].

Core Viewpoint - The article emphasizes the importance of international scientific cooperation and highlights China's role as a strong advocate and active practitioner in this field, particularly through the achievements of Chinese scientists like Zhang Lina in addressing global challenges through innovative research [1][6]. Group 1: Zhang Lina's Contributions - Zhang Lina, a polymer physicist, began her research career at the age of 46 and won the highest international award in her field at 71, demonstrating significant achievements in the study of cellulose and chitin [1][6]. - She successfully developed a low-temperature dissolution technology using NaOH/urea aqueous solution, which allows for the efficient dissolution of cellulose and chitin, overcoming traditional thermal dissolution limitations [4][5]. - Her innovations have led to the creation of various high-performance materials, including fibers, films, hydrogels, and aerogels, which are widely applied in textiles, biomedicine, energy storage, and wastewater treatment [4][5]. Group 2: Recognition and Impact - In March 2011, Zhang Lina received the Anselm Payen Award from the American Chemical Society, marking her as the first Chinese scientist to win this prestigious award in nearly fifty years [6]. - Her dual recognition through international awards and domestic honors signifies China's growing research strength in the field of renewable resources and its increasing respect on the global stage [6]. - Zhang Lina's journey illustrates that scientific innovation is not limited by age, inspiring many researchers to pursue their passions and contribute to significant advancements at any stage of their careers [8].